Novel Topical Intradermal Formulation and Uses Thereof

The European Patent Office published Arctic Therapeutics hf.'s patent application EP3843732A1 covering a novel topical formulation for intradermal application. The formulation uses specific chemical compositions (A61K 31/445, A61K 47/10, A61K 47/14) for dermatological therapeutic applications targeting psoriasis and skin conditions. The patent is designated across 31 European states including all major EU markets, Switzerland, the UK, Norway, and Turkey.

Pharmaceutical and biotechnology companies developing topical dermatological treatments should conduct freedom-to-operate analyses to assess potential overlap with this protected formulation. Generic manufacturers and biosimilar developers should evaluate the scope of the A61K compound claims and consider potential design-around strategies before advancing products in European markets.